Description

Amphomycin is a lipopeptide antibiotic that inhibits peptidoglycan synthesis and blocks cell wall development. Amphomycin exhibits potent antibacterial activities against methicillin-resistant S. aureus (MRSA), vancomycin-resistant enterococci (VRE), penicillin-gentamicin-erythromycin-resistant S. pneumonia, and linezolid-quinupristin-dalfopristin-resistant enterococci[1][2][3].—COVID-19-immunoregulation–N/A—-[1]Singh M, et al. Solid-state NMR characterization of amphomycin effects on peptidoglycan and wall teichoic acid biosyntheses in Staphylococcus aureus. Sci Rep. 2016 Aug 19;6:31757. |[2]Pasetka CJ, et al. Novel antimicrobial lipopeptides with long in vivo half-lives. Int J Antimicrob Agents. 2010 Feb;35(2):182-5. |[3]Tanaka H, et al. Amphomycin inhibits phospho-N-acetylmuramyl-pentapeptide translocase in peptidoglycan synthesis of Bacillus. Biochem Biophys Res Commun. 1979 Feb 14;86(3):902-8. –1402-82-0–N/A—-[Amphomycin]–Infection–10 mM in DMSO–Antibiotic;Bacterial–Lipopeptide–Anti-infection–Peptides